Cancer's hiding spots matter: study reveals organs react differently to immunotherapy
NCT ID NCT07631611
First seen Jun 16, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This study looked at medical records of 938 adults with solid tumors to see how cancers that spread to different organs—like the liver, brain, lung, or bone—respond to immunotherapy. The goal is to understand why some metastatic sites respond better than others and to help doctors personalize treatment. Researchers also analyzed molecular data to explore the biological reasons behind these differences.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4 inhibitors)
What this could lead to
If successful, this could help doctors choose better immunotherapy treatments based on where a patient's cancer has spread.
What could go wrong
This is a retrospective study that looks back at medical records, so it cannot prove cause and effect. Results may not apply to all patients or treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.